"Peramivir is an important part of our influenza preparedness program," said Miguel Angel Toscana, Federal Commissioner of COFEPRIS (Mexico's Federal Commission for the Protection against Sanitary Risk).  "Approval of peramivir importation will help our mission of protecting our nation."

The 2009 H1N1 influenza A virus is a new influenza virus and one to which most people have no or little immunity and, therefore, this virus could cause more infections than are seen with seasonal flu.  The severity of the disease ranges from very mild symptoms to severe illnesses that can result in death.

In September 2009, moksha8 signed a binding letter of intent to exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing and distribution of peramivir for seasonal influenza upon local regulatory approval, in certain Latin American countries, including Brazil and Mexico.  

moksha8 also announced that it has raised $25 million in a Series C financing led by Montreux Equity Partners.  Existing investor TPG Biotechnology and CEO, Simba Gill, also participated in the financing.